Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C

Clinical Pharmacokinetics

Volumn 55, Issue 11, 2016, Pages 1337-1351

  German, Polina ^a   Mathias, Anita ^a   Brainard, Diana ^a   Kearney, Brian P ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FAMOTIDINE; GS 331007; HEMOGLOBIN; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; OMEPRAZOLE; PLACEBO; RIBAVIRIN; SOFOSBUVIR; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ABNORMAL LABORATORY RESULT; AREA UNDER THE CURVE; CHILD PUGH SCORE; CHRONIC HEPATITIS C; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; ELIMINATION HALF-LIFE; END STAGE RENAL DISEASE; FATIGUE; FOOD; FOOD DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INSOMNIA; KIDNEY FAILURE; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHYSICAL EXAMINATION; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; QT PROLONGATION; RENAL CLEARANCE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; ANALOGS AND DERIVATIVES; ANIMAL; DOSE RESPONSE; DRUG INTERACTION; HALF LIFE TIME; HEPATITIS C, CHRONIC; METABOLIC CLEARANCE RATE; METABOLISM; PH; SUSTAINED VIROLOGIC RESPONSE;

ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUORENES; HALF-LIFE; HEPATITIS C, CHRONIC; HUMANS; HYDROGEN-ION CONCENTRATION; LIVER FAILURE; METABOLIC CLEARANCE RATE; RENAL INSUFFICIENCY; SUSTAINED VIROLOGIC RESPONSE; URIDINE MONOPHOSPHATE;

EID: 84969921197     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-016-0397-0     Document Type: Review

References (56)

1. TM (telaprevir) film coated tablets. US Prescribing Information. Cambridge: Vertex Pharmaceuticals Incorporated; 2013.
2. ® (boceprevir) Capsules for oral use. U.S. Prescribing Information. Whitehouse Station. Revised September 2013.
3. Wyles DL. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med. 2012;20(4):139–45.
4. ® (sofosbuvir) tablets, for oral use. US Prescribing Information. Foster City. Revised August 2015.
5. SOVALDI 400 mg film-coated tablets. Summary of product characteristics. Cambridge: Gilead Sciences Limited; 2015.
6. ® (sofosbuvir) 400 mg tablets for oral use. Product monograph. 2015.
7. ® (ledipasvir and sofosbuvir) tablets, for oral use. US prescribing information. Foster City. Revised March 2015.
8. HARVONI (ledipasvir/sofosbuvir) 90 mg/400 mg film-coated tablet. Summary of product characteristics. Cambridge: Gilead Sciences International Limited; 2014.
9. Gilead Sciences Inc., Harvoni (Ledipasvir/Sofosbuvir) tablets for oral use. Swiss prescribing information. Approved 16 December 2014.
10. HARVONI™ (Ledipasvir/Sofosbuvir) tablets 90 mg/400 mg Antiviral agent. Product monograph. Foster City: Gilead Sciences Inc; Revised October 14 2014.
11. Amidon GL, Lennernäs H, Shah VP et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20.
12. Link J, Bannister R, Beilke L et al. Nonclinical profile and phase I results in healthy volunteers of the novel and potent HCV NS5A inhibitor GS-5885 [Poster 1883]. In: 61st annual meeting of the American Association for the Study of Liver Diseases (AASLD), Boston; 677–690 2010.
13. Babusis D, Curry MP, Denning JM et al. Translational studies to understand the mechanism of liver delivery by sofosbuvir [Presentation]. In: 15th international workshop on clinical pharmacology of HIV and hepatitis therapy. Washington, D. C.; 2014.
14. German P, Pang PS, Fang L et al. Drug-drug interaction profile of the fixed-dose combination tablet ledipasvir/sofosbuvir [Presentation #1976]. In: The 65th annual meeting of the American Association for the Study of Liver Diseases: The Liver Meeting (AASLD), Boston; 2014.
15. ® (sofosbuvir) tablets, for oral use. US Prescribing Information. Foster City; Revised March 2015.
16. German P, Mathias A, Pang PS et al. Lack of clinically significant pharmacokinetic drug-drug interaction between sofosbuvir (GS-7977) and GS-5885 or GS-9669 in healthy volunteers [Poster 1888]. In: 63rd annual meeting of the American Association for the Study of Liver Diseases. Boston: Gilead Sciences, Inc.; 2012.
17. German P, Yang J, West S et al. Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of ledipasvir/sofosbuvir fixed-dose combination tablet [Poster P_15]. In: 15th international workshop on clinical pharmacology of HIV & hepatitis therapy. Washington, DC; 2014.
18. ® (FAMOTIDINE) TABLETS. US prescribing information. Whitehouse Station; Revised February 2010.
19. Atanassoff PG, Brull SJ, Weiss BM et al. The time course of gastric pH changes induced by omeprazole and ranitidine: a 24-hour dose-response study. Anesth Analg. 1995;80(5):975–9.
20. ® (Omeprazole magnesium) for delayed-release oral suspension. U.S. prescribing information. Revised March 2014.
21. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100(1):190–200.
22. Mogalian E, Mathias A, Yang J et al. The Pharmacokinetics of ledipasvir, an HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment [Poster 1952]. In: The 65th annual meeting of the American Association for the Study of Liver Diseases: the liver meeting (AASLD), Boston; 2014.
23. German P, Mathias A, Yang J et al. Pharmacokinetics of ledipasvir, an HCV-specific NS5A inhibitor, in HCV-uninfected subjects with moderate or severe hepatic impairment [Poster 467]. In: 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting. Washington, D. C.; 2013.
24. Kirby B, Mathias A, Yang C et al. Metabolism and excretion of ledipasvir (GS-5885) in humans [abstract O_20]. In: 8th international workshop on clinical pharmacology of hepatitis therapy. Cambridge, MA; June 26–27, 2013.
25. Murakami E, Tolstykh T, Bao H et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010;285(45):34337–47.
26. Babusis D, Curry MP, Denning JM et al. Nucleotide analog levels in liver explants from HCV infected subjects undergoing liver transplantation after up to 24 weeks sofosbuvir (GS-7977) with ribavirin treatment [Poster 1091]. In: 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD). Washington, DC.; 2013.
27. Kirby BJ, Symonds WT, Kearney BP et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54(7):677–90.
28. Cornpropst M, Denning JM, Clemons D et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977 [Abstract 1100]. Presented at: 47th annual meeting of the European Association for the Study of the Liver (EASL); 2012 April 18–22; Barcelona, Spain. J Hepatol. 2012;56:S433.
29. Lawitz EJ, Gruener D, Hill JM et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol. 2012;57(1):24–31.
30. Mo H, Yang C, Wang K et al. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors. J Viral Hepat. 2011;18(5):338–48.
31. ® 2013 The 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Washington D.C.; 2013.
32. Rodriguez-Torres M, Lawitz E, Kowdley KV et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. J Hepatol. 2013;58:663–8.
33. Kirby B, Hanbin L, Kearney BP et al. Population Pharmacokinetics analysis of ledipasvir (GS-5885) in healthy and hepatitis C virus-infected subjects [Presentation of Poster P_33]. In: 15th international workshop on clinical pharmacology of HIV and hepatitis therapy. Washington, D. C.; 2014.
34. Marshall WL, Yeh WW, Stypinski D et al. Age and gender effects on the pharmacokinetics of HCV NS5A inhibitor MK-8742 [Presentation]. In: International workshop on clinical pharmacology of HIV and hepatitis therapy. Washington, D. C.; 2014.
35. ® (declatasvir) 30 mg film-coated tablets for oral use. Summary of product characteristics. Date of first authorisation: 22 August 2014.
36. Sulkowski M, et al. SVR12 rates in treatment-Naïve HCV genotype 1a and 1b patients treated with an interferon-free all-oral regimen [Oral Presentation 212]. In: AASLD. Boston; 2012.
37. Wyles DL, Rodriguez-Torres M, Lawitz E et al. All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. Hepatology. 2014;60(1):56–64. doi:10.1002/hep.27053.
38. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93.
39. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88.
40. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Guidance for Industry. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Rockville; 2005. p. 1–20.
41. Cornpropst M, Denning JM, Clemons D et al. PSI-7977 Has no effect on QTCF intervals at therapeutic or supratherapeutic doses [Abstract 391]. Presented at Conference: 62nd annual meeting of the American Association for the Study of Liver Diseases: the liver meeting 2011 San Francisco, CA United States. Conference Start: 20111104 Conference End: 20111108. Hepatology. 2011; 54 (4 (Suppl)):553A.
42. German P, Pang PS, Wu X et al. Evaluation of the effect of ledipasvir on the QT/QTc interval in healthy subjects [Poster P_47]. In: 15th international workshop on clinical pharmacology of HIV and hepatitis therapy. Washington, D. C.; 2014.
43. National Instiutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002–June 10–12, 2002. Hepatology. 2002;36(5 Suppl 1):S3–20.
44. Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004;12(2):96–102.
45. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER), Guidance for Industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Rockville; 2003. p. 1–16.
46. Lawitz E. Rodriguez-Torres M, Cornpropst M et al. The effect of hepatic impairment on the safety, pharmacokinetics, and antiviral activity of GS-7977 in hepatitis C infected subjects treated for seven days [Poster 1130]. In: 47th annual meeting of the European Association for the Study of the Liver (EASL). Barcelona; 2012.
47. Gane E, Manns MP, McCaughan G et al. High efficacy of ledipasvir/sofosbuvir with ribavirin in patients with decompensated cirrhosis or liver transplantation and HCV infection: combined efficacy from the SOLAR-1 and SOLAR-2 trials. In: American Association for the Study of Liver Diseases (AASLD). San Francisco; 2015.
48. Samuel D, Manns M, Forns X et al. Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post-liver transplantation patients with HCV infection: an integrated safety analysis of the SOLAR-1 and SOLAR-2 Trials. In: European Association for the Study of the Liver (EASL). The 50th International Liver Congress. Vienna; 2015.
49. Gordon CE, Balk EM, Becker BN et al. KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD. Am J Kidney Dis. 2008;52(5):811–25.
50. U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER), Guidance for Industry. Pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling. 2010. p. 1–21.
51. Martin P, Gane E, Ortiz-Lasanta G et al. Safety and Efficacy of treatment with daily sofosbuvir 400 mg + Ribavirin 200 mg for 24 weeks in genotype 1 or 3 HCV-infected patients with severe renal impairment [Poster 1128]. In: American Association for the Study of Liver Diseases (AASLD). San Francisco; 2015.
52. Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol. 2012;18(2):99–104.
53. Lackner H, Moser A, Deutsch J et al. Interferon-alpha and ribavirin in treating children and young adults with chronic hepatitis C after malignancy. Pediatrics. 2000;106(4):E53.
54. Wirth S, Lang T, Gehring S et al. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology. 2002;36(5):1280–4.
55. Kirby B, German P, Kanwar B et al. Pharmacokinetics of once-daily sofosbuvir and ledipasvir/sofosbuvir in HCV-infected adolescents [Poster 1707]. In: American Association for the Study of Liver Diseases (AASLD). San Francisco; 2015.
56. Kearns GL, Abdel-Rahman SM, Alander SW et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. New Engl J Med. 2003;349(12):1157–67.